STEP Young Explained: Semaglutide in Children Aged 6 to 11, What “40.4% Below the Obesity Threshold” Means, and Why It Says Nothing About Compounded GLP-1s
Published: Updated: Provider pricing verified:
On September 7, 2026 Novo Nordisk reported that its phase 3 STEP Young trial met its primary endpoint in children aged 6 to under 12. This is the first large randomised result for a GLP-1 in that age group. Here is what was reported, what was not, and where it does — and does not — touch the cash-pay market this site covers.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD · Published September 9, 2026 · Last reviewed September 9, 2026 · Sources cited at the end.
Direct answer
STEP Young randomised 165 children aged 6 to under 12 with obesity (more than 85% with class II or III obesity) to once-weekly subcutaneous semaglutide at 1.7 mg or 2.4 mg (by baseline weight) or placebo, with a reduced-calorie diet and increased physical activity in both arms, for 68 weeks, with follow-up to 104 weeks. The primary endpoint — a greater reduction in BMI than placebo at week 68 — was met. 40.4% of children on semaglutide finished below the obesity threshold for their age and sex, against 0% on placebo. Novo reports safety consistent with earlier paediatric and adult trials and no signal on growth or pubertal development; full data go to ObesityWeek (November 14–17, 2026). Wegovy is approved from age 12; no filing timeline was given. None of this applies to compounded semaglutide or tirzepatide, which are not FDA-approved, not studied in children and not appropriate for minors through a cash-pay program.
How to read a “below the obesity threshold” endpoint
In children, obesity is defined against age- and sex-specific BMI percentiles, not a fixed BMI. “Below the threshold” means a child’s BMI fell under the 95th percentile for their age and sex at week 68. The 40.4% figure is a responder proportion — how many crossed a line — not the average BMI change, which the topline release quantifies only as “greater than placebo”. Two things the number does not tell you: the size of the mean BMI reduction, and what happens after treatment stops. Both will matter more than the headline when the full results are presented.
What was reported, in one table
| Item | Reported |
|---|---|
| Participants | 165 children, 6 to <12 years, with obesity; >85% class II or III |
| Design | Randomised, double-blind, placebo-controlled; reduced-calorie diet and increased activity in both arms |
| Dose | Semaglutide 1.7 mg or 2.4 mg weekly, assigned by baseline weight |
| Duration | 68 weeks to the primary endpoint; supportive endpoints to 104 weeks |
| Primary endpoint | Greater BMI reduction than placebo at week 68 — met |
| Responder result | 40.4% below the obesity threshold on semaglutide vs 0% on placebo |
| Safety | Consistent with prior paediatric/adult semaglutide and liraglutide trials; no new concerns; none for growth or pubertal development |
| Next | Detailed results at ObesityWeek 2026, November 14–17, Washington, DC; no regulatory timeline stated |
Why this does not reach the compounded market
- Different product. STEP Young used Novo Nordisk’s semaglutide under a protocol; compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed for safety, effectiveness or quality.
- Different patients. Every telehealth program in our index prescribes to adults (SnagRx states 19+ in Nebraska; the others 18+). A trial in six-year-olds is not evidence for, or a pathway to, cash-pay use in minors.
- Different economics. If a paediatric indication follows, it will be a coverage question. The cash-pay channel’s prices — Wegovy pen $349 ($199 introductory), pill $149–$299, compounded programs $119–$258 — are adult self-pay prices.
Our news ledger tracks the regulatory side at /news; the pricing side is on the price index.
Medical note (Dr. Jonathan Snipes, MD, medical reviewer): childhood obesity treatment belongs with a paediatrician; this article summarises a company-reported topline result that has not yet been peer-reviewed or presented in full. It is not a recommendation for any medication in any age group.
Medical and regulatory note: compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality; they are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice. Consult a licensed clinician before starting, stopping or changing any medication, and confirm the price and prescribing requirements with the provider before enrolling.
Frequently asked questions
What did the STEP Young trial find? Novo Nordisk reported on September 7, 2026 that in 165 children aged 6 to under 12 with obesity, once-weekly semaglutide (1.7 or 2.4 mg) plus lifestyle changes produced a greater BMI reduction than placebo at 68 weeks; 40.4% of treated children finished below the obesity threshold versus 0% on placebo.
Is Wegovy approved for children under 12? No. Wegovy is approved for weight management from age 12. STEP Young is a topline result; full data are due at ObesityWeek (November 14–17, 2026) and no filing timeline was announced.
Were there safety problems in STEP Young? Novo reports safety and tolerability consistent with earlier paediatric and adult semaglutide and liraglutide trials, no new safety concerns, and none identified for growth or pubertal development. Detailed adverse-event data have not been published yet.
Can a child get compounded semaglutide or tirzepatide online? No legitimate cash-pay telehealth program in our index prescribes to minors, and compounded GLP-1s are not FDA-approved or studied in children. Childhood obesity care belongs with a paediatrician.
What does 'below the obesity threshold' mean for a child? Childhood obesity is defined by age- and sex-specific BMI percentiles (obesity is at or above the 95th percentile). The 40.4% figure is the share of treated children whose BMI fell below that line at week 68 — a responder proportion, not the average BMI change.
Does this change adult GLP-1 prices? No. Adult self-pay prices read September 9, 2026: Wegovy pen $349 ($199 for the first two months through December 31, 2026), Wegovy pill $149–$299, Zepbound vials $299–$449 on LillyDirect, compounded tirzepatide programs $119–$258 per month.
September 9, 2026: Published.
Reviewed by Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD
Sources
- Novo Nordisk — STEP Young phase 3 topline press release, September 7, 2026 (read 2026-09-09)
- Bloomberg — Novo Nordisk's Wegovy Helps Kids as Young as Six With Obesity (September 7, 2026)
- NovoCare — Wegovy self-pay prices (read 2026-09-09)
- FDA — Human Drug Compounding: compounded drugs are not FDA-approved
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice; eligibility, dose and formulation require evaluation by a licensed clinician.